Charlotte Höybye
Charlotte Höybye
Department of Endocrinology and Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Beverly M K Biller
Beverly M K Biller
Neuroendocrine Unit, Massachusetts General Hospital, Massachusetts General Hospital, Boston, Massachusetts, USA
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Jean-Marc Ferran
Jean-Marc Ferran
Qualiance ApS, Copenhagen, Denmark
Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Murray B Gordon
Murray B Gordon
Allegheny Neuroendocrinology Center, Division of Endocrinology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Nicky Kelepouris
Nicky Kelepouris
US Medical Affairs-Rare Endocrine Disorders, Novo Nordisk, Inc, Plainsboro, New Jersey, USA
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Navid Nedjatian
Navid Nedjatian
Global Medical Affairs – Rare Endocrine Disorders, Novo Nordisk Health Care AG, Zurich, Switzerland
Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Anne H Olsen
Anne H Olsen
Epidemiology, Novo Nordisk A/S, Soborg, Denmark
Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Matthias M Weber
Matthias M Weber
Unit of Endocrinology, 1, Medical Department, University Hospital, Universitätsmedizin Mainz, der Johannes Gutenberg-Universität, Mainz, Germany
Search for other papers by Matthias M Weber in
Google Scholar
PubMed
Search for other papers by Matthias M Weber in
Google Scholar
PubMed
. Mean ( s.d. ) duration of exposure was 5.2 (4.3) years for females and 5.7 (4.7) years for males in the NordiNet ® IOS population and 3.7 (3.4) years for females and 3.7 (3.6) for males in the ANSWER Program population (both FAS). A total of 265 GH
